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Disorders of distal acidification
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The final site of titration of the urinary buffers is the collecting
tubule. When this process fails urinary acid excretion is unable
to match the 1 to 1.5 mEq/kg body weight of nonvolatile acid
generated daily as a consequence of the high protein diet
consumed by most Westerners. The clinical expression of such
a defect is distal renal tubular acidosis (dRTA). Over the past
decade numerous laboratory and clinical studies have clearly
demonstrated that dRTA is a group of syndromes which results
from a variety of defects in distal urinary acidification.
If 100 mEq of nonvolatile acid are generated a day, the kidney
must reclaim all of the filtered bicarbonate and excrete 100 mEq
of acid to preserve homeostasis. Since the urine pH cannot fall
below about 4.5, the acid must be excreted in buffered form as
titratable acid or as ammonium. Though the nephron can
reabsorb bicarbonate along its entire length, bicarbonate recla-
mation is mainly a proximal event. Similarly, the tubule titrates
the urinary buffers at all sites. The collecting tubule, however,
is the location of the greatest lowering of urinary pH and bears
the major responsibility for acid excretion.
In this paper I will discuss the mechanisms that might be
responsible for the clinical syndromes of renal tubular acidosis
and present a classification of these disorders. Many of these
mechanisms can only tentatively be offered as a model since our
knowledge is not far enough advanced to be certain about them.
The model will doubtless require modification as more informa-
tion is obtained.
Mechanisms of distal acidification
Acid is secreted in both the cortical and medullary collecting
tubules. The intercalated cells of these segments clearly have
been implicated in this process [1]. These cells contain carbonic
anhydrase as well as an H-ATPase which, depending on its
location, mediates proton or bicarbonate secretion, the former
when it's on the apical membrane, the latter when it's on the
basolateral membrane. There is also evidence, however, that
the principal cell of the cortical collecting tubule (CCT) partic-
ipates in acidification [2], at least under some circumstances.
Oubain stimulates CCT acidification in tubules that have had
carbonic anhydrase inhibited, as does basolateral amiloride
when applied to CCT from starved rabbits [2]. The oubain effect
is blocked by luminal amiloride. These data indicate that the
sodium transporting cells, the principal cells, acidify the urine.
This interpretation is based on the following assumptions.
Carbonic anhydrase inhibition abolishes acidification in the
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intercalated cells, thus the stimulation of acidification seen ii
this circumstance following oubain must be due to an effect ot
the principal cell. In addition luminal amiloride should onl3
affect the cell with a sodium channel. By raising cell sodium
oubain would decrease basolateral sodium-hydrogen exchange
which then would stimulate apical proton secretion. The nex
assumption is that basolateral amiloride is blocking a basolat
eral sodium-hydrogen exchanger in a sodium transporting cell
As was true for oubain, this would lower cell pH and stimulat
apical proton secretion.
In addition to the H-ATPase, data are accumulating tha
suggest that another proton pump also modulates collectinl
tubule proton secretion, the H-K-ATPase [3, 4]. This trans
porter appears identical to the gastric acid pump and is in
hibitable by omeprazole and vanadate. It is stimulated b
potassium depletion. Figures 1 to 3 depict the model of hydro•
gen secretion postulated in the collecting tubule. Before dis.
cussing it, however, I must caution that much of it is theoretical
and requires experimental verification before it can be ac
cepted.
The CCT, according to the model, contains principal celb
which actively transport sodium and which contain the H-KS
ATPase at the luminal membrane, while a sodium-hydrogen
exchanger is at the serosal surface (Fig. 1). Potassium depletion
would enhance acid secretion by this transporter. Thus the
postulated role of the H-K-ATPase in this cell is to regulate
potassium absorption and cell PH; it would also contribute
somewhat to overall acid-base regulation. The source of the
protons extruded at both plasma membranes is likely metabolic
acid which does not require carbonic anhydrase for its genera-
tion. There is also a chloride-bicarbonate exchanger on the
basolateral membrane (not shown on Fig. 1) which will extrude
bicarbonate only when luminal proton secretion exceeds baso-
lateral proton transport [5].
The CCT also has intercalated cells, though in much lower
number, which contain the H-ATPase and, I believe, the
H-K-ATPase as well [1]. Some of these intercalated cells have
the H-ATPase at the apical membrane (alpha cells) (Fig. 2),
while others have the pump at the basolateral surface (beta
cells) (Fig. 3). The beta cell also appears to have a sodium-
hydrogen exchanger at its basolateral membrane (not shown)
[5]. I think it likely the H-K-ATPase is present only in the alpha
cells. The medullary collecting tubule (MCT) contains only
principal cells and alpha intercalated cells [1].
Aldosterone stimulates the sodium pump (whether directly or
indirectly is irrelevant to the model), increases passive potas-
sium secretion, and increases H-ATPase activity. It does not
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stimulate the H-K-ATPase. Thus aldosterone excess is associ-
ated with potassium wastage and excess acid secretion while
aldosterone deficiency is associated with potassium retention
and acid retention.
This model explains a variety of clinical and laboratory
observations which have been difficult to integrate. For exam-
ple, the combination of hypokalemia and aldosterone excess is
associated with increased acid excretion and metabolic alkalo-
sis, while potassium depletion alone is usually accompanied by
metabolic acidosis. Steroid excess would stimulate CCT so-
dium absorption which would increase lumen negative voltage
and thus enhance electrogenic (H-ATPase) driven acidification.
Steroid excess would also stimulate the H-ATPase directly in
both CCT and MCT and further increase acid excretion. Potas-
sium depletion would stimulate the H-K-ATPase as well, fur-
ther enhancing acid excretion.
By contrast, potassium depletion alone would decrease aldo-
sterone release thus inhibiting the H-ATPase both directly and
indirectly via voltage. The stimulatory effect of potassium
depletion on H-K-ATPase would mitigate the loss of H-ATPase
activity, explaining the variable acid-base status which charac-
terizes patients and animals with pure potassium depletion.
Sodium sulfate infusion and furosemide administration both
stimulate distal acidification [6, 7]. This has been attributed to
HC03 increased lumen negative voltage in the CCT. The furosemide
effect is blocked by amiloride, which further supports the
voltage hypothesis [7]. An additional explanation is possible,
however. Furosemide (and sulfate as well) might stimulate
acidification by increasing potassium delivery which would
enhance electrically neutral H-K exchange. Amiloride would
block this effect by lowering cell sodium concentration which
would enhance basolateral sodium-hydrogen exchange, which
in turn would reduce luminal proton secretion (Fig. 1).
This mechanism does not exclude a sodium dependent effect
of furosemide or sulfate on acidification. Under this scenario
increasing distal sodium delivery with an poorly reabsorbable
anion, that is, sulfate or chloride in the presence of furosemide,
would increase CCT lumen negative voltage and enhance both
proton and potassium secretion.
There are at least five mechanisms that could fail and cause
defective distal acidification, each of which will be discussed in
detail below (Table 1). Either of the proton pumps might be
damaged. A defect in the H-K-ATPase should cause hypokale-
mic dRTA. This might be the mechanism of classical dRTA. If
the H-ATPase were deranged a normokalemic form of RTA
should eventuate. Impaired CCT sodium transport would im-
pair voltage and cause hyperkalemic acidosis. Similarly, aldo-
sterone deficiency or resistance would also cause hyperkalemic
acidosis. Finally, an inability to maintain a steep pH gradient
across the distal nephron would also cause metabolic acidosis.
Tests of urinary acidification
Bicarbonate reabsorption
Since most of the filtered bicarbonate is reabsorbed in the
proximal tubule, measurement of bicarbonate reabsorption is a
test of proximal acidification [8]. Expression of bicarbonate
Fig. 1. Theoretical model of principal cell acidification. There is also a
chloride-bicarbonate exchanger and a potassium channel on the baso-
lateral membrane that have been omitted for simplicity's sake.
Fig. 2. Model of the alpha (proton secreting) cell of the collecting
tubule. CA = carbonic anhydrase
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Table 1. Potential causes of dRTA
Defect Syndrome
H-KATPase activity Hypokalemic dRTA
H-ATPase activity Normokalemic dRTA
CCT Na transport Voltage-dependent
(hyperkalemic) dRTA
Aldosterone deficiency or Hyperkalemic metabolic acidosis
resistance with low urine pH
Capacity to maintain steep pH Hyperchloremic metabolic
gradients acidosis with normal UpCO2a
a The hypokalemia typical of amphotericin induced dRTA is due to
increased cell permeability to potassium rather than decreased potas-
sium transport capacity.
reabsorption per liter of glomerular filtrate facilitates interpa-
tient comparison. Measuring bicarbonate reabsorption over a
wide range of plasma bicarbonate concentrations provides the
maximum amount of information about proximal bicarbonate
reclamation. Because it requires infusing bicarbonate over
several hours, the test is seldom used clinically. Much easier,
and therefore more widely used, is fractional bicarbonate
excretion. Maximal bicarbonate reabsorption is normal in pa-
tients and animals with defective distal acidification. Since
small amounts of bicarbonate are reabsorbed in the collecting
tubule, fractional bicarbonate excretion is increased in dRTA.
It usually is 5 to 10%. An excretion of more than 15% indicates
a proximal defect.
Urine pCO2
When the urine is rich in bicarbonate the urine pCO2 reaches
a value about 40 mm Hg or more greater than that of the blood.
This rise is predominately the consequence of collecting tubule
proton secretion [9—111. Since luminal carbonic anhydrase is
not present in this segment the titration of bicarbonate gener-
ates carbonic acid which dehydrates to CO2 and water slowly.
The CO2 thus produced is formed in the terminal nephron and
in the lower urinary tract where the surface to volume relation-
ship is unfavorable for back diffusion. Impairment of distal
proton secretion, irrespective of the mechanism, will impair the
kidney's ability to increase urine pCO2 during bicarbonate
diuresis. Thus this test is very sensitive and equally nonspecific.
To yield interpretable results sufficient bicarbonate should be
administered to raise urinary bicarbonate concentration to at
least 100 mEq/liter and the urine pH should exceed 7.8 for at
least 30 minutes prior to the collection of the test sample.
Urine pH
The normal kidney promptly excretes an acid urine in re-
sponse to acidemia [121. When the blood pH falls below 7.35 the
urine pH almost invariably is less than 5.5; the only exceptions
are impaired distal delivery of sodium and defective distal
acidification. The former can easily be detected by measuring
urine sodium concentration.
Sodium sulfate
Failure to lower urine pH during acidemia because of dimin-
ished distal sodium delivery can be eliminated by infusing
sodium sulfate [121. This procedure results in a prompt lowering
of urine pH and in an increase in both potassium and ammo-
nium excretion. The mechanisms that may mediate this re-
sponse and that to furosemide have already been discussed. As
typically performed, 500 ml of a 4% solution are infused over
about an hour. Urine collection should continue for two to three
hours since some patients have a delayed response.
Furosemide administration
Although the sodium sulfate test provides much useful infor-
mation, it is cumbersome and difficult to perform. The recently
developed furosemide test gives the same information much
more conveniently [7]. A dose of 40 to 80 mg of furosemide is
given orally. Urine is collected 120 to 180 minutes later when
the maximum acidification response occurs.
Urinary ammonium and the urine anion gap
A normal renal response to acidemia includes an increase in
urinary ammonium excretion. If ammonium excretion goes up
under this circumstance renal acidification is intact regardless
of whether urine pH falls or not. Conversely, urinary acidifica-
tion is impaired if it does not rise irrespective of how low the
urine pH falls. Urinary ammonium is not usually measured in
patients. The amount of ammonium in urine can be estimated,
however, by determining the urine anion gap, define as (Na +
K) — Cl [13]. A urine rich in ammonium will have a negative
anion gap, ie there will be considerably more chloride present
that sodium plus potassium; the missing cation is ammonium.
Renal tubular acidosis syndromes
Classical dRTA
As originally described, dRTA was a syndrome of hypokale-
mia, hyperchloremic metabolic acidosis, inability to lower urine
pH below 5.5, nephrocalcinosis and nephrolithiasis, and osteo-
malacia or renal rickets [14—16]. Until about a decade ago the
disorder was thought to have a single pathogenesis: an inability
to generate and maintain a steep pH gradient in the distal
nephron [17]. In other words, the distal nephron was thought to
secrete protons normally, but because the tubule was "leaky"
the acid back-diffused across the terminal nephron and was
returned to the blood.
A series of animal experiments cast doubt on this hypothesis.
As previously mentioned the urine pCO2 is a very sensitive
means of assessing distal hydrogen ion secretion. If a gradient
defect were responsible for classical dRTA then the urine pCO2
should rise normally in afflicted subjects, since the urine pH is
high during bicarbonate diuresis and prevents a lumen to blood
acid gradient. This was confirmed by experiments in amphoter-
icin treated rats which showed the capacity to generate CO2 to
be intact [18]. Earlier experiments in turtle bladder, a tight
epithelium and an analogue of the collecting tubule, had shown
that amphotericin interferes with acidification solely by increas-
ing acid back-diffusion [19]. Thus amphotericin is a model of
gradient dRTA. When patients with dRTA were studied they
were shown to have an impairment of urinary CO, generation
during bicarbonate loading [20]. Thus, their defect appeared to
be one of impaired proton secretion rather than increased acid
back-diffusion.
At present the only form of dRTA thought to be secondary to
a gradient defect is that induced by amphotericin. I must
emphasize, however, that almost all the pertinent amphotericin
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Table 2. Features of voltage-dependent dRTA
1. Salt wastage—detectable only with marked salt restriction
2. Hyperkalemic hyperchloremic metabolic acidosis
3. Normal or increased plasma aldosterone
4. Low urine pCO2 with bicarbonate loading
5. Urine pH >5.5
6. Abnormal response to sulfate or furosemide administration
data come from animal studies. For this issue to be completely
resolved urine pCO2 data in patients with amphotericin neph-
rotoxicity are needed.
The best explanation currently available for the hypokalemic
form of dRTA is to postulate inhibition of the H-K-ATPase.
Such a mechanism has the virtue of explaining all the features of
classical dRTA, but rests on an inadequate data base. If this
enzyme were a major regulator of both potassium and acid-base
homeostasis then its failure would cause hypokalemic hyper-
chloremic metabolic acidosis with all the feature associated
with classical dRTA.
Examination of Figure 1 shows that failure of the pump would
divert metabolic acid produced in the principal cell to the
circulation, and cause potassium wastage. The failure of the
H-K-ATPase in alpha intercalated cell as well would cancel any
adaptive response by the H-ATPase and thus ensure the devel-
opment of systemic acidosis.
Irrespective of the etiology of this syndrome, relentless acid
retention rapidly exhausts extracellular buffers. Blood pH can
then only be defended by tapping another source of buffer; the
only pool big enough to satisfy this need is the skeleton.
Accordingly, basic calcium salts are continually leached from
bone. The clinical sequelae are hypercalciuria, nephrocalcino-
sis, and nephrolithiasis as well as osteomalacia or renal rickets
depending on the age of the patient.
Voltage-dependent RTA
Obstruction of a ureter for as little as 24 hours results in an
acidification defect that is apparent immediately following relief
of the obstruction [211. The lesion is also characterized by
impaired potassium excretion and reduced mineralocorticoid-
stimulated sodium reabsorption. For these reasons the collect-
ing duct was implicated as the major site of involvement.
Because administration of the potassium sparing diuretic amil-
oride caused an identical defect, amiloride was though to impair
the same mechanism as urinary tract obstruction [22].
Studies with amiloride in the turtle bladder revealed that the
drug interfered with acidification only indirectly [23]. When the
tissue was voltage clamped amiloride had no effect on proton
secretion. In the open circuited state, however, it reduced
acidification in tandem with its reduction of the transepithelial
potential difference. This suggested that there was a major
voltage dependent component of acidification. The CCT
seemed to be the logical site of this mechanism. Experiments in
rabbit collecting tubule were consistent with this view [24].
Amiloride and oubain inhibited acidification in CCT, but not in
MCT where active sodium transport was said not to occur.
A syndrome of voltage dependent dRTA was postulated to
exist [25]. Its features included hyperkalemic hyperchioremic
metabolic acidosis, an inability to lower urine pH, and a normal
or elevated plasma aldosterone concentration (Table 2). Shortly
thereafter patients with urinary tract obstruction who fulfilled
these criteria were reported [261. Patients with hemoglobin S
were also shown to have an identical impairment of both acid
and potassium excretion [27].
More recent studies from our laboratory suggest that the
effects of urinary tract obstruction on acidification are more
complicated than we initially thought. Collecting tubules taken
from the post-obstructed rabbit kidney showed decreased acid-
ification only in the MCT [28]. In fact, acidification was
increased in CCT after 24 hours of obstruction. Obviously, this
finding is not consistent with a voltage mechanism.
Study of H-ATPase activity post-unilateral ureteral obstruc-
tion showed a decrease in enzyme activity in both CCT and
MCT, but the decline was much more profound in the latter
[29]. Na-K-ATPase activity was depressed along the entire
nephron. This study suggests that, in addition to a voltage
mechanism, obstruction directly affects the (or a) proton pump
in the MCT. Finally, preliminary data from our lab indicates
that amiloride administration inhibits H-ATPase activity in both
CCT and MCT [30]. This suggests that amiloride has a mecha-
nism of action different from that postulated above or that
sodium dependent acidification occurs in the MCT as well as
the CCT.
Lithium administration to animals in toxic amounts causes
dRTA [31]. This disorder is not associated with hyperkalemia,
though the defect in acidification induced by lithium in the turtle
bladder is identical to that caused by amiloride [32]. We
explained this lack of hyperkalemia by postulating that lithium
interfered with potassium reabsorption proximal to the CCT.
The finding of a voltage-induced impairment of proton secretion
should be associated with a decrease in H-ATPase activity in
the CCT, which is what we recently found [301. As with
amiloride, we also found a decrease in MCT as well. This
decrease in H-ATPase activity in both CCT and MCT is
consistent with the decrease in urinary pCO2 observed in
patients receiving therapeutic doses of lithium [33]. It also
suggests that lithium interferes with acidification by doing more
than just reducing CCT transepithelial voltage.
What's lacking in all of these studies is the role of the
H-K-ATPase in mediating both normal and deranged acidifica-
tion. For example, urinary tract obstruction and amiloride
might decrease H-ATPase activity while stimulating the H-K-
ATPase. Depending on the degree of stimulation and inhibition
of the two proton pumps overall acidification and potassium
excretion might both be reduced.
Lithium, on the other hand, might reduce H-ATPase activity
without stimulating the H-K pump. This would explain the
absence of hyperkalemia in lithium treated animals and its
greater (than amiloride) propensity to causes systemic acidosis.
Studies of the H-K-ATPase currently underway will likely
resolve these questions.
Normokalemic dRTA
Some patients with moderately advanced renal insufficiency
have dRTA with neither potassium wastage nor retention [20].
This syndrome also is seen in patients with chronic transplant
rejection [34]. I think its cause is impaired H-ATPase activity in
the collecting tubule. If this enzyme failed, but the H-K-ATPase
and the Na-K-ATPase were both intact then normokalemic
dRTA should ensue.
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This syndrome is almost always acquired, and is commonly
seen in patients with interstitial nephropathy who usually have
substantial reductions in glomerular filtration rate. Because
renal insufficiency markedly reduces urinary calcium excretion,
these patients do not have nephrolithiasis or nephrocalcinosis.
Both the hypokalemic and normokalemic forms of dRTA can
easily be treated with the daily administration of 50 to 100 mEq
of bicarbonate or citrate.
Rate dependent-RTA
There is a group of patients with reduced renal function
(usually due to interstitial nephropathy) who have a subtle
defect in distal acidification [35]. They cannot raise the urine
pCO2 in response to a bicarbonate load; in all other respects
their ability to acidify appears normal. They typically do not
have acidosis. We termed this disorder rate-dependent dRTA
and proposed that the definition of incomplete dRTA be broad-
ened to include patients without overt acidosis who cannot raise
the urine pCO2, but who can lower urine pH. Our reasoning was
that the urine pCO2 reflects the rate of distal acidification and
that a moderate decrease in that rate might be reflected only by
a decreased urine pCO,. Only a handful of patients with
rate-dependent dRTA have been described. Whether the defect
is of more than marginal clinical importance is uncertain. It is
likely that the syndrome represents an early stage of one of the
other forms of RTA that may ultimately progress to an overt
state.
Aldosterone deficiency and resistance
Although originally described more than 30 years ago [36],
the syndrome of isolated aldosterone deficiency has been rec-
ognized with regularity only during the past decade and a half
[37—40]. The hallmarks of the disorder are hyperkalemia and
hyperchioremic metabolic acidosis. Because aldosterone exerts
its effects on electrolyte transport on the collecting tubule the
disorder had been grouped with the renal tubular acidoses; it is
commonly called type IV dRTA. Since type I and type II are
infrequently used to describe distal and proximal renal tubular
acidosis, since there is no type III, and since aldosterone
resistance and voltage dependent dRTA have similar features
and are both often called type IV RTA, the term lacks precision
and should be discarded. Aldosterone deficiency is preferable
as it identifies the primary defect and suggests the appropriate
therapy.
As noted above, aldosterone directly stimulates collecting
tubule acidification by increasing proton secretion and indi-
rectly by enhancing sodium absorption. Thus its absence results
in acid retention; however, the ability to generate and maintain
pH gradients across the distal nephron is not reduced in this
case. The ability to lower urine pH in the face of aldosterone
deficiency is generally attributed to decreased urine ammonia
generation which is characteristic of the syndrome [41, 42]. It
doesn't take much to lower urine pH when urinary buffer
concentration is low.
Aldosterone deficiency should slow the overall rate of distal
proton secretion. To the extent that the urinary pCO2 reflects
this parameter the data are problematic. We have been unable
to show the aldosterone deficiency lowers the urine pCO2 [41,
43]. DuBose and Caflisch [18], however, have shown a de-
crease. Again, the missing piece of the puzzle may be the effect
of aldosterone on the H-K-ATPase. In the absence of aldoste-
rone H-ATPase activity should markedly fall. That of the
H-K-ATPase should be unaffected. Persistent H-K-ATPase
activity may play a role in the amiloride inhibitable fraction of
urinary acidification seen in aldosterone deficient subjects [43}.
When amiloride is given to adrenalectomized animals the
urinary pCO2 falls dramatically [43]. This demonstrates that
there is a major component of distal acidification that is
aldosterone independent and sodium dependent. This aldoste-
rone independent component of acidification appears to medi-
ate the response to saline loading in aldosterone deficient
animals. This maneuver completely corrects the acidosis of
mineralocorticoid deficiency and underlies the favorable re-
sponse of patients with the disorder to diuretic therapy and salt
administration [41]. When distal delivery is high, aldosterone
deficiency is virtually without manifestation. When it is reduced
hyperkalemia and metabolic acidosis are obvious.
While the story of aldosterone dependent and independent
acidification is still incomplete, it is absolutely clear that pa-
tients with pure aldosterone deficiency can lower the urine pH
normally during acidemia [26]. This capacity is extremely useful
in distinguishing this syndrome from voltage dependent renal
tubular acidosis.
Aldosterone resistance
For every endocrine deficiency disease there is a resistance
state [40]. The features of the resistance state are the same as
those of the deficiency syndrome, except that the hormone in
question (in this case aldosterone) is present in normal or
increased concentrations. Thus the blood levels in aldosterone
resistance and voltage-dependent dRTA are the same. The
distinguishing characteristic is that patients with aldosterone
resistance can lower their urine pH normally, while those with
voltage-dependent dRTA cannot.
A form of aldosterone resistance is seen in children that is
associated with profound salt wastage far in excess of the
deficiency or resistance syndromes of adults [44—46]. The
difference may attributable, at least in part, to the normal
glomerular filtration rate present in these children.
Another form of adult aldosterone resistance occurs in adults
that presents with salt retention rather than wastage; its patho-
genesis has been attributed to enhanced chloride permeability
in the CCT [47, 48]. If chloride is reabsorbed across the CCT in
increased amounts ( a so-called chloride shunt), the tubule
cannot sustain the negative charge that usually prevails. The
loss of this charge, in turn, secondarily reduces both proton and
potassium secretion. Excess salt reabsorption also generates
volume-dependent hypertension. Patients with this disorder
respond normally to sulfate or furosemide administration, un-
like those with voltage-dependent dRTA.
Evaluation
The approach to a patient with hyperchloremic metabolic
acidosis begins with the examination of the urine. If the acidosis
is the result of an extrarenal disorder, such as diarrhea, the
urine will be rich in ammonium. This can easily be disclosed by
measuring the urinary electrolytes. There will be considerably
more chloride than sodium plus potassium, usually >50 mEq/
liter. In other words, the anion gap will be minus 50 or more.
Patients with dRTA or related syndromes typically have more
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Clinical approach to the classification
of renal tubular acidosis
Hyperchloremic
acidosis with
normal or low
plasma potassium
Urine pH
during acidosis
I I I I
Exclude proximal renal
tubular acidosis,
measure ammonium and Diagnose distal
titratable acidity, renal tubular
measure urine PCO2 acidosis if
during sodium bicarbonate
bicarbonate infusion excretion is
(i.e., look for a "rate not high
dependent" defect(
Fig. 4. Class(fication of RTA in patients with normal or low potassium
concentration. Adapted from reference 49.
Hyperchloremic
acidosis with
hyperkalemia
Urine pH
during acidosis
Determine
plasma
cortisol
Low Normal
Adrenal Selective
insufficiency aldosterone
deficiency
Fig. 5. Classification of RTA in patients with hyperkalemia. Adapted
from reference 49.
cation then chloride in their urine when they are acidemic,
indicating the presence of defective acidification. Once the
diagnosis of an RTA syndrome has been made the urinary anion
gap has no further use since it is abnormal in all of them.
As shown in Figures 4 and 5, the next step is to divide the
patients according to the serum potassium, those with a normal
or low serum potassium and those in whom it is elevated. The
first group (Fig. 4) can be further subdivided into those patients
who can lower the urine pH below 5.5 and those who cannot.
When proximal RTA had been excluded, distal RTA can be
Table 3. Patterns of plasma aldosterone and urine pH
Urine pH
during acidemia
Plasma
aldosterone
Aldosterone deficiency
Aldosterone resistance
Voltage-dependent distal
RTA
Aldosterone deficiency
and voltage-dependent
distal RTA combined
<5.5
<5.5
>5.5
>5.5
Low
Normal or high
Normal or high
Low
diagnosed with certainty in those whose urine pH is greater
than 5.5. As mentioned above, the defect in those patients
whose potassium is normal is hypothetically ascribed to a
defect in the H-ATPase, while those with hypokalemia are
thought to have impairment of the H-K-ATPase. Patients who
can lower urine pH below 5.5 should have proximal RTA
excluded. They then can be given sodium bicarbonate intrave-
nously; if the urine pCO2 fails to rise normally, the diagnosis of
rate dependent dRTA can be made.
Patients with hyperkalemia should also be divided on the
basis of urine pH (Fig. 5). In those with a pH below 5.5 a normal
plasma cortisol combined with a low aldosterone establishes the
diagnosis of selective aldosterone deficiency. Since hyperkale-
mia stimulates aldosterone release, plasma aldosterone values
cannot accurately be interpreted without reference to the serum
potassium concentration. When the potassium is normal or
elevated, the plasma aldosterone concentration should be at
least three times higher. Thus an aldosterone of 15 ng/ml, while
ostensibly normal, is low for a patient with a potassium of 6
mEq/liter. If both cortisol and aldosterone and cortisol are low,
the patient has Addison's disease. A normal cortisol and a low
aldosterone characterizes selective aldosterone deficiency. The
finding of a normal or high aldosterone suggests aldosterone
resistance. In patients with hyperkalemia and a urine pH
persistently greater than 5.5, the diagnosis of hyperkalemic or
voltage dependent dRTA is made without further evaluation,
but one should look for a specific cause such as obstructive
uropathy or hemoglobin S.
Table 3 shows the pattern of plasma aldosterone and urine pH
seen in patients with aldosterone deficiency, aldosterone resis-
tance, voltage dependent dRTA, and the combination of aldo-
sterone deficiency and RTA. Note that the patient with the
combined disorder is easily distinguished from those with the
other disorders. The high urine pH indicates dRTA and the low
aldosterone discloses the steroid deficiency.
Principles of treatment
The normokalemic and hypokalemic forms of dRTA require
only small amounts of orally administered bicarbonate, or its
equivalent. Because the distal nephron modulates only about
100 mEq of acid excretion a day, the maximum amount of
bicarbonate necessary to treat a patient with dRTA is 100 mEq
a day. In practice, considerably less is required since most of
these patients retain the ability to excrete some acid. Children
are an exception to this rule because of the large alkali require-
ment of growing bone. If the defect in hypokalemic patients is
a damaged H-K-ATPase, then potassium supplementation may
have to be continued even after the acidosis has been corrected.
Aldosterone
resistance
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Additional studies of potassium balance in these patients are
needed to carefully examine this issue.
Patients with hyperkalemic (voltage-dependent) dRTA
should first have their underlying disease treated, if one is
identified and is amenable to treatment. Obstructive uropathy is
of course the most important example. In general, distal sodium
delivery should be encouraged by ingestion of generous
amounts of salt to stimulate whatever residual capacity for CCT
sodium transport remains. Because many patients with this
syndrome have renal and cardiovascular disease, increased
dietary salt can result in edema rather than in increased distal
delivery of sodium, but this problem can be overcome by the
addition of furosemide to the high salt diet. This combination
encourages the distal delivery of salt and stimulates CCT acid
and potassium excretion, to the extent that this capacity re-
mains intact.
Mineralocorticoid therapy is sometimes useful in patients
with aldosterone deficiency, although increasing distal sodium
delivery is usually sufficient. Giving steroid without increasing
distal sodium delivery can precipitate heart failure. This com-
plication can be avoided with diuretic administration and a diet
high in salt, since salt restriction exacerbates hyperkalemia and
metabolic acidosis. Other forms of treatment, such as potas-
sium exchange resin and alkali, may also be necessary.
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